ES2085983T3 - Antagonistas de anticuerpos de la interleuquina-4 humana. - Google Patents

Antagonistas de anticuerpos de la interleuquina-4 humana.

Info

Publication number
ES2085983T3
ES2085983T3 ES91902038T ES91902038T ES2085983T3 ES 2085983 T3 ES2085983 T3 ES 2085983T3 ES 91902038 T ES91902038 T ES 91902038T ES 91902038 T ES91902038 T ES 91902038T ES 2085983 T3 ES2085983 T3 ES 2085983T3
Authority
ES
Spain
Prior art keywords
antibodies
antagonists
link
cell receptors
antibody antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902038T
Other languages
English (en)
Spanish (es)
Inventor
Lata Ramanathan
Gail F Seelig
Paul P Trotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2085983T3 publication Critical patent/ES2085983T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES91902038T 1989-12-20 1990-12-18 Antagonistas de anticuerpos de la interleuquina-4 humana. Expired - Lifetime ES2085983T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45357089A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
ES2085983T3 true ES2085983T3 (es) 1996-06-16

Family

ID=23801108

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902038T Expired - Lifetime ES2085983T3 (es) 1989-12-20 1990-12-18 Antagonistas de anticuerpos de la interleuquina-4 humana.

Country Status (26)

Country Link
US (1) US6358509B1 (https=)
EP (1) EP0506826B1 (https=)
JP (1) JPH0730116B2 (https=)
KR (1) KR960016862B1 (https=)
AT (1) ATE136906T1 (https=)
AU (1) AU639754B2 (https=)
CA (1) CA2071908C (https=)
CZ (1) CZ283050B6 (https=)
DE (1) DE69026627T2 (https=)
DK (1) DK0506826T3 (https=)
ES (1) ES2085983T3 (https=)
FI (1) FI104180B1 (https=)
GR (1) GR3020325T3 (https=)
HU (1) HU215245B (https=)
IE (1) IE74708B1 (https=)
IL (1) IL96714A0 (https=)
MX (1) MX9203401A (https=)
MY (1) MY106507A (https=)
NO (1) NO922457D0 (https=)
NZ (1) NZ236511A (https=)
OA (1) OA09704A (https=)
PT (1) PT96230B (https=)
SK (1) SK635290A3 (https=)
TW (1) TW221675B (https=)
WO (1) WO1991009059A1 (https=)
ZA (1) ZA9010190B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1995007301A1 (en) * 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
MXPA01006006A (es) 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
DE60135170D1 (de) * 2000-04-06 2008-09-18 Fujifilm Corp Farbstoffkomplex und optisches Informationsaufzeichnungsmedium
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
AU2003251633A1 (en) * 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
RU2382049C2 (ru) * 2004-08-03 2010-02-20 Новартис Аг ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ-4 (hIL-4)
NZ592943A (en) * 2008-11-17 2012-09-28 Uinv Kobenhavns Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2018108836A (ru) 2011-02-04 2019-03-14 Дженентек, Инк. ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
BR122021009041B1 (pt) 2014-05-06 2022-11-29 Genentech, Inc Métodos para a preparação de uma proteína heteromultimérica
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80678A (en) * 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
ZA872781B (en) 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
DE68908431T2 (de) * 1988-02-02 1993-12-23 Schering Biotech Corp Methode zur Verminderung der Immunglobulin-E-Reaktion.

Also Published As

Publication number Publication date
ZA9010190B (en) 1991-08-28
MY106507A (en) 1995-06-30
HU215245B (hu) 1998-11-30
NO922457L (no) 1992-06-19
ATE136906T1 (de) 1996-05-15
SK279933B6 (sk) 1999-06-11
IE74708B1 (en) 1997-07-30
HU9202073D0 (en) 1992-09-28
CA2071908A1 (en) 1991-06-21
HUT64568A (en) 1994-01-28
FI922847A0 (fi) 1992-06-18
NZ236511A (en) 1993-02-25
GR3020325T3 (en) 1996-09-30
FI104180B (fi) 1999-11-30
MX9203401A (es) 1992-07-01
DE69026627D1 (de) 1996-05-23
PT96230B (pt) 1998-06-30
AU639754B2 (en) 1993-08-05
JPH04506359A (ja) 1992-11-05
FI104180B1 (fi) 1999-11-30
TW221675B (https=) 1994-03-11
CZ283050B6 (cs) 1997-12-17
CZ635290A3 (en) 1997-08-13
FI922847L (fi) 1992-06-18
CA2071908C (en) 2002-04-30
NO922457D0 (no) 1992-06-19
EP0506826B1 (en) 1996-04-17
IL96714A0 (en) 1991-09-16
JPH0730116B2 (ja) 1995-04-05
OA09704A (en) 1993-08-30
EP0506826A1 (en) 1992-10-07
IE904589A1 (en) 1991-07-03
SK635290A3 (en) 1999-06-11
AU7176291A (en) 1991-07-18
KR960016862B1 (ko) 1996-12-23
DK0506826T3 (da) 1996-05-13
US6358509B1 (en) 2002-03-19
WO1991009059A1 (en) 1991-06-27
DE69026627T2 (de) 1996-08-22
KR920703642A (ko) 1992-12-18
PT96230A (pt) 1991-10-15

Similar Documents

Publication Publication Date Title
ES2085983T3 (es) Antagonistas de anticuerpos de la interleuquina-4 humana.
ATE57690T1 (de) Pyrazolin mit insektizidischer aktivitaet.
ES2173873T3 (es) Utilizacion de anticuerpos anti-vegf para el tratammiento del cancer.
ES2058083T3 (es) Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo.
ES2059413T3 (es) Anticuerpos monoclonales contra antigenos asociados a melanoma, progenies celulares hibridas que producen estos anticuerpos, y su empleo correspondiente.
ES2109228T3 (es) Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso.
ES2149772T3 (es) Receptores humanos pf4a y su utilizacion.
ES2138977T3 (es) Agonistas muscarinicos.
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
ES2153444T3 (es) Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.
DE69428290D1 (de) Derivate von alpha-hordothionin mit höherem behalt an lysin
ES2053719T3 (es) Dimetilvermectinas no naturales y procedimiento para su preparacion.
ES2043607T3 (es) Agentes fibrinoliticos modificados.
ES2047014T3 (es) Procedimiento para preparar un catalizador basado en plata y procedimiento para epoxidar olefinas superiores.
ES2091292T3 (es) Metodo para la determinacion inmunologica del polipeptido carboxiterminal de procolageno de tipo i.
ES2147761T3 (es) Metodo para la deteccion de alteraciones de los huesos y otros tejidos conectivos en los seres humanos y los animales.
ATE103147T1 (de) Stuhlkonstruktion zum aufbau von stuhlreihen.
ES2091816T3 (es) Anticuerpos monoclonales del factor estimulador de colonias de macrofagos (m-csf) que reconocen un epitope conformacional neutralizante.
MX9300602A (es) Analogos de fenilalanina de bombesina.
ES2131218T3 (es) Utilizacion de anticuerpos anti-idiotipicos para evitar el rechazo hiperagudo de los injertos entre dos especies diferentes.
ES2052913T3 (es) Ensayo inmunoquimico en cuanto al factor estimulante de colonias de granulocitos-macrofagos.
ES8303449A1 (es) "procedimiento para la preparacion de compuestos derivados de alfa-d-galactopiranosido".
ES2044893T3 (es) Un anticuerpo monoclonal especifico para un inhibidor de la coagulacion.
BG40660A3 (en) Device for fixing connecting terminals of symmetric cables

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506826

Country of ref document: ES